Identification of a Six-Gene Signature for Predicting the Overall Survival of Cervical Cancer Patients

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Johnson CA, James D, Marzan A, Armaos M. Cervical cancer: an overview of pathophysiology and management. Semin Oncol Nurs. 2019;35(2):166–174. doi:10.1016/j.soncn.2019.02.003
   PubMed Web of Science ®Google Scholar
• Shen F, Zheng H, Zhou L, Li W, Liu J, Xu X. Identification of CD28 and PTEN as novel prognostic markers for cervical cancer. J Cell Physiol. 2019;234(5):7004–7011. doi:10.1002/jcp.27453
   PubMed Web of Science ®Google Scholar
• Mao X, Qin X, Li L, et al. A 15-long non-coding RNA signature to improve prognosis prediction of cervical squamous cell carcinoma. Gynecol Oncol. 2018;149(1):181–187. doi:10.1016/j.ygyno.2017.12.011
   PubMed Web of Science ®Google Scholar
• Wei Q, Ma C, Zhang W, et al. Identification of a microRNA signature associated with survivability in cervical squamous cell carcinoma. PLoS One. 2018;13(3):e0193625. doi:10.1371/journal.pone.0193625
   PubMed Web of Science ®Google Scholar
• Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12(4). doi:10.1186/gb-2011-12-4-r41
   PubMed Web of Science ®Google Scholar
• Jeremy MG, Taylor P. Random survival forests. J Thorac Oncol. 2011;6:1974–1975. doi:10.1097/JTO.0b013e318233d835
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287. doi:10.1089/omi.2011.0118
   PubMed Web of Science ®Google Scholar
• Li YL, Ye F, Cheng XD, et al. Identification of glia maturation factor beta as an independent prognostic predictor for serous ovarian cancer. Eur J Cancer (Oxford, England: 1990). 2010;46(11):2104–2118. doi:10.1016/j.ejca.2010.04.015
   PubMed Web of Science ®Google Scholar
• Zhang SF, Wang XY, Fu ZQ, et al. TXNDC17 promotes paclitaxel resistance via inducing autophagy in ovarian cancer. Autophagy. 2015;11(2):225–238. doi:10.1080/15548627.2014.998931
   PubMed Web of Science ®Google Scholar
• Chen H, Deng Q, Wang W, Tao H, Gao Y. Identification of an autophagy-related gene signature for survival prediction in patients with cervical cancer. J Ovarian Res. 2020;13(1):131. doi:10.1186/s13048-020-00730-8
   PubMed Web of Science ®Google Scholar
• Mei J, Xing Y, Lv J, et al. Construction of an immune-related gene signature for prediction of prognosis in patients with cervical cancer. Int Immunopharmacol. 2020;88:106882. doi:10.1016/j.intimp.2020.106882
   PubMed Web of Science ®Google Scholar
• Pan J, Xu L, Pan H. Development and validation of an m6A RNA methylation regulator-based signature for prognostic prediction in cervical squamous cell carcinoma. Front Oncol. 2020;10:1444. doi:10.3389/fonc.2020.01444
   PubMed Web of Science ®Google Scholar
• Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–1953. doi:10.1002/ijc.31937
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.21262
   PubMed Web of Science ®Google Scholar
• Menderes G, Black J, Schwab CL, Santin AD. Immunotherapy and targeted therapy for cervical cancer: an update. Expert Rev Anticancer Ther. 2016;16(1):83–98. doi:10.1586/14737140.2016.1121108
   PubMed Web of Science ®Google Scholar
• Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001;358(9284):781–786. doi:10.1016/S0140-6736(01)05965-7
   PubMed Web of Science ®Google Scholar
• Bhutiani N, Egger ME, Ajkay N, Scoggins CR, Martin RCG, McMasters KM. Multigene signature panels and breast cancer therapy: patterns of use and impact on clinical decision making. J Am Coll Surg. 2018;226(4):406–412.e401. doi:10.1016/j.jamcollsurg.2017.12.043
   PubMed Web of Science ®Google Scholar
• Lin G, Yang L-Y, Lin Y-C, et al. Prognostic model based on magnetic resonance imaging, whole-tumour apparent diffusion coefficient values and HPV genotyping for stage IB-IV cervical cancer patients following chemoradiotherapy. Eur Radiol. 2018;29(2):556–565. doi:10.1007/s00330-018-5651-4
   PubMed Web of Science ®Google Scholar
• Mao Y, Fu Z, Dong L, Zheng Y, Dong J, Li X. Identification of a 26-lncRNAs risk model for predicting overall survival of cervical squamous cell carcinoma based on integrated bioinformatics analysis. DNA Cell Biol. 2019;38(4):322–332. doi:10.1089/dna.2018.4533
   PubMed Web of Science ®Google Scholar
• Inoue H, Iga M, Xin M, et al. TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model. Cancer Immunol Immunother. 2008;57(9):1399–1411. doi:10.1007/s00262-008-0476-7
   PubMed Web of Science ®Google Scholar
• Hirata A, Hashimoto H, Shibasaki C, Narumi K, Aoki K. Intratumoral IFN-α gene delivery reduces tumor-infiltrating regulatory T cells through the downregulation of tumor CCL17 expression. Cancer Gene Ther. 2019;26(9–10):334–343. doi:10.1038/s41417-018-0059-5
   PubMed Web of Science ®Google Scholar
• Semmling V, Lukacs-Kornek V, Thaiss CA, et al. Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs. Nat Immunol. 2010;11(4):313–320. doi:10.1038/ni.1848
   PubMed Web of Science ®Google Scholar
• Okada N, Sasaki A, Niwa M, et al. Tumor suppressive efficacy through augmentation of tumor-infiltrating immune cells by intratumoral injection of chemokine-expressing adenoviral vector. Cancer Gene Ther. 2006;13(4):393–405. doi:10.1038/sj.cgt.7700903
   PubMed Web of Science ®Google Scholar
• Nishioka M, Tanemura A, Yang L, Tanaka A, Arase N, Katayama I. Possible involvement of CCR4+ CD8+ T cells and elevated plasma CCL22 and CCL17 in patients with rhododenol-induced leukoderma. J Dermatol Sci. 2015;77(3):188–190. doi:10.1016/j.jdermsci.2015.02.014
   PubMed Web of Science ®Google Scholar
• Zhan Q, Shen B, Fang Y, et al. Drug-eluting scaffold inhibited in vivo pancreatic tumorigenesis by engaging murine CCR4(+)CD8(+) T cells. Colloids Surf B Biointerfaces. 2017;158:469–473. doi:10.1016/j.colsurfb.2017.07.021
   PubMed Web of Science ®Google Scholar
• Liu LB, Xie F, Chang KK, et al. Chemokine CCL17 induced by hypoxia promotes the proliferation of cervical cancer cell. Am J Cancer Res. 2015;5(10):3072–3084.
   PubMed Web of Science ®Google Scholar
• Li J, Yang C, Yang J, Zou L. Down-regulation of CCL17 in cancer-associated fibroblasts inhibits cell migration and invasion of breast cancer through ERK1/2 pathway. Cancer Manag Res. 2019;11:7439–7453. doi:10.2147/CMAR.S211651
   PubMed Web of Science ®Google Scholar
• Al-haidari AA, Syk I, Jirström K, Thorlacius H. CCR4 mediates CCL17 (TARC)-induced migration of human colon cancer cells via RhoA/Rho-kinase signaling. Int J Colorectal Dis. 2013;28(11):1479–1487. doi:10.1007/s00384-013-1712-y
   PubMed Web of Science ®Google Scholar
• Al-Haidari AA, Syk I, Thorlacius H. HMG-CoA reductase regulates CCL17-induced colon cancer cell migration via geranylgeranylation and RhoA activation. Biochem Biophys Res Commun. 2014;446(1):68–72. doi:10.1016/j.bbrc.2014.02.078
   PubMed Web of Science ®Google Scholar
• Hnia K, Ramspacher C, Vermot J, Laporte J. Desmin in muscle and associated diseases: beyond the structural function. Cell Tissue Res. 2015;360(3):591–608. doi:10.1007/s00441-014-2016-4
   PubMed Web of Science ®Google Scholar
• Bhunia S, Barbhuiya MA, Gupta S, Shrivastava BR, Tiwari PK. Epigenetic downregulation of desmin in gall bladder cancer reveals its potential role in disease progression. Indian J Med Res. 2020;151(4):311–318. doi:10.4103/ijmr.IJMR_501_18
   PubMed Web of Science ®Google Scholar
• Geier R, Adler S, Rashid G, Klein A. The synthetic estrogen diethylstilbestrol (DES) inhibits the telomerase activity and gene expression of prostate cancer cells. Prostate. 2010. doi:10.1002/pros.21166
   PubMed Web of Science ®Google Scholar
• Arentz G, Chataway T, Price TJ, et al. Desmin expression in colorectal cancer stroma correlates with advanced stage disease and marks angiogenic microvessels. Clin Proteomics. 2011;8(1):16. doi:10.1186/1559-0275-8-16
   PubMedGoogle Scholar
• Wang Y, Li Y, Chen Z. The evaluation of colorectal cancer risk in serum by anti-DESMIN-conjugated CdTe/CdS quantum dots. Clin Lab. 2017;63(3):579–586. doi:10.7754/Clin.Lab.2016.161005
   PubMed Web of Science ®Google Scholar
• Nita-Lazar M, Noonan V, Rebustini I, Walker J, Menko AS, Kukuruzinska MA. Overexpression of DPAGT1 leads to aberrant N-glycosylation of E-cadherin and cellular discohesion in oral cancer. Cancer Res. 2009;69(14):5673–5680. doi:10.1158/0008-5472.CAN-08-4512
   PubMed Web of Science ®Google Scholar
• Jamal B, Sengupta PK, Gao ZN, et al. Aberrant amplification of the crosstalk between canonical Wnt signaling and N-glycosylation gene DPAGT1 promotes oral cancer. Oral Oncol. 2012;48(6):523–529. doi:10.1016/j.oraloncology.2012.01.010
   PubMed Web of Science ®Google Scholar
• Li R, Xu T, Wang H, et al. Dysregulation of the miR-325-3p/DPAGT1 axis supports HBV-positive HCC chemoresistance. Biochem Biophys Res Commun. 2019;519(2):358–365. doi:10.1016/j.bbrc.2019.08.116
   PubMed Web of Science ®Google Scholar
• Zhou YZM, Wei H, Zhou H, He J, Lu Y. Furin promotes epithelial-mesenchymal transition in pancreatic cancer cells via Hippo-YAP pathway. Int J Oncol. 2017;50:1352–1362. doi:10.3892/ijo.2017.3896
   PubMed Web of Science ®Google Scholar
• Lee M, Ryu CH, Chang HW, Kim GC, Kim SW, Kim SY. Radiotherapy-associated furin expression and tumor invasiveness in recurrent laryngeal cancer. Anticancer Res. 2016;36(10):5117–5126. doi:10.21873/anticanres.11081
   PubMed Web of Science ®Google Scholar
• Bassi DE, Zhang J, Renner C, Klein-Szanto AJ. Targeting proprotein convertases in furin-rich lung cancer cells results in decreased in vitro and in vivo growth. Mol Carcinog. 2017;56(3):1182–1188. doi:10.1002/mc.22550
   PubMed Web of Science ®Google Scholar
• Ju M, Qi A, Bi J, et al. A five-mRNA signature associated with post-translational modifications can better predict recurrence and survival in cervical cancer. J Cell Mol Med. 2020;24(11):6283–6297. doi:10.1111/jcmm.15270
   PubMed Web of Science ®Google Scholar
• Shin IWCVY, Siu MT, Tsang JY, et al. Association of EP2 receptor and SLC19A3 in regulating breast cancer metastasis. Am J Cancer Res. 2015;5(11):3389–3399.
   PubMed Web of Science ®Google Scholar
• Ng EK, Leung CP, Shin VY, et al. Quantitative analysis and diagnostic significance of methylated SLC19A3 DNA in the plasma of breast and gastric cancer patients. PLoS One. 2011;6(7):e22233. doi:10.1371/journal.pone.0022233
   PubMed Web of Science ®Google Scholar
• Fu L, Qin YR, Ming XY, et al. RNA editing of SLC22A3 drives early tumor invasion and metastasis in familial esophageal cancer. Proc Natl Acad Sci U S A. 2017;114(23):E4631–e4640. doi:10.1073/pnas.1703178114
   PubMed Web of Science ®Google Scholar
• Ren A, Sun S, Li S, et al. Genetic variants in SLC22A3 contribute to the susceptibility to colorectal cancer. Int J Cancer. 2019;145(1):154–163. doi:10.1002/ijc.32079
   PubMed Web of Science ®Google Scholar